- Conditions
- Malignant Melanoma
- Interventions
- ABI-007, Dacarbazine
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 529 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 33 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1129–1152
of 7,459
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- AMG 282, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 4
- States / cities
- Santa Monica, California • Aurora, Colorado • South Miami, Florida + 1 more
- Conditions
- Migraine, Migraine Disorders, Headache
- Interventions
- Amitriptyline, Topiramate, Placebo
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • San Francisco, California • Stanford, California + 32 more
- Conditions
- Transgender, Gender Identity, Vascular Stiffness, Vascular Inflammation, Insulin Sensitivity, Blood Pressure, Lipid Disorder, Appetitive Behavior
- Interventions
- No intervention
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hematologic Neoplasms
- Interventions
- Enasidenib
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 19
- States / cities
- Duarte, California • Stanford, California • Aurora, Colorado + 14 more
- Conditions
- Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
- Interventions
- Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 18 Months
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 193
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more
- Conditions
- Urothelial Cancer
- Interventions
- Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 19
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 4 more
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- Osimertinib, Nivolumab, Telisotuzumab vedotin, Erlotinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
- Conditions
- Outcomes, Survival Rates
- Interventions
- CMX001
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 100 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 47
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Postoperative Atelectasis, Postoperative Hypoxemia, Postoperative Pneumonia, Postoperative Pulmonary Complications, Patient Adherence, Incentive Spirometry, Respiratory Therapy, Respiratory Insufficiency
- Interventions
- Alarms
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Breast Cancer
- Interventions
- Raloxifene, Tamoxifen
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 19,747 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 492
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 369 more
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- pramlintide acetate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 104 more
- Conditions
- Idiopathic Inflammatory Myopathies
- Interventions
- Placebo, Nerandomilast
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 23
- States / cities
- Scottsdale, Arizona • Irvine, California • Los Angeles, California + 19 more
- Conditions
- Parkinson Disease
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 17
- States / cities
- Sun City, Arizona • San Francisco, California • Aurora, Colorado + 14 more
- Conditions
- DCIS, Ductal Carcinoma in Situ
- Interventions
- Surgery, Active Monitoring
- Other
- Lead sponsor
- Alliance Foundation Trials, LLC.
- Other
- Eligibility
- 40 Years to 99 Years · Female only
- Enrollment
- 997 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 141
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 117 more
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Oral Budesonide Suspension (OBS), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 11 Years to 55 Years
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium, Oxaliplatin
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 110
- States / cities
- Greenbrae, California • Aurora, Colorado • Boulder, Colorado + 76 more
- Conditions
- Hyperlipidemia, Dyslipidemia
- Interventions
- torcetrapib/atorvastatin, ezetimibe/simvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 123
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma, Glioblastoma, Glioblastoma Multiforme, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Midline Glioma, H3K27-altered
- Interventions
- Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post Radiation
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2035
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Interventions
- Abatacept, Normal Saline, D5W
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide, Lenalidomide
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 44
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 34 more
- Conditions
- End of Life, Communication, Cancer Metastatic
- Interventions
- Novel Communication Intervention, Enhanced Usual Care Parent Education
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Wilmington, Delaware • Atlanta, Georgia + 4 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Saquinavir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 16
- States / cities
- Palo Alto, California • San Francisco, California • Torrance, California + 10 more
- Conditions
- Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Ventricular Arrhythmia
- Interventions
- Catheter ablation
- Device
- Lead sponsor
- Heart Rhythm Clinical and Research Solutions, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 64 more